Does amputation offer any survival benefit over limb salvage in osteosarcoma patients with poor chemonecrosis and close margins?

Bone and Joint Journal

Volumn 97-B, Issue 1, 2015, Pages 115-120

  Reddy, K I A ^a   Wafa, H ^b   Gaston, C L ^c   Grimer, R J ^c   Abudu, A T ^c   Jeys, L M ^c   Carter, S R ^c   Tillman, R M ^c  

^a Medical Center East   (United States)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c ROYAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; BONE LESION; BONE METASTASIS; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; LIMB AMPUTATION; LIMB SALVAGE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OSTEOSARCOMA; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; SURGICAL ANATOMY; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR NECROSIS; TUMOR RECURRENCE; ADJUVANT RADIOTHERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; LIMB DISEASE; OSTEOSARCOMA OF THE LIMB; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 84925232319     PISSN: 20494394     EISSN: 20494408     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776-790.
2. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994;12:423-431.
3. Simon MA, Aschliman MA, Thomas N, Mankin HJ. Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. J Bone Joint Surg [Am] 1986;68-A:1331-1337.
4. Rougraff BT, Simon MA, Kneisl JS, Greenberg DB, Mankin HJ. Limb salvage compared with amputation for osteosarcoma of the distal end of the femur. A longterm oncological, functional, and quality-of-life study. J Bone Joint Surg [Am] 1994;76-A:649-656.
5. Sluga M, Windhager R, Lang S, et al. Local and systemic control after ablative and limb sparing surgery in patients with osteosarcoma. Clin Orthop Relat Res 1999;358:120-127.
6. Bacci G, Ferrari S, Lari S, et al. Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg [Br] 2002;84-B:88-92.
7. Kong CB, Song WS, Cho WH, Oh JM, Jeon DG. Local recurrence has only a small effect on survival in high-risk extremity osteosarcoma. Clin Orthop Relat Res 2012;470:1482-1490.
8. Bacci G, Ferrari S, Longhi A, et al. Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Eur J Cancer 2001;37:32-38.
9. Machak GN, Tkachev SI, Solovyev YN, et al. Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. Mayo Clin Proc 2003;78:147-155.
10. DeLaney TF, Park L, Goldberg SI, et al. Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys 2005;61:492-498.
11. Bramwell VH, Burgers M, Sneath R, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol 1992;10:1579-1591.
12. Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997;350:911-917.
13. Lewis IJ, Nooij MA, Whelan J, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007;99:112-128.
14. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980;153:106-120.
15. Picci P, Bacci G, Campanacci M, et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer 1985;56:1515-1521.
16. Grimer RJ, Taminiau AM, Cannon SR; Surgical Subcommitte of the European Osteosarcoma Intergroup. Surgical outcomes in osteosarcoma. J Bone Joint Surg [Br] 2002;84-B:395-400.
17. Glasser DB, Lane JM, Huvos AG, Marcove RC, Rosen G. Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience. Cancer 1992;69:698-708.
18. Bielack SS, Kempf-Bielack B, Winkler K. Osteosarcoma: relationship of response to preoperative chemotherapy and type of surgery to local recurrence. J Clin Oncol 1996;14:683-684.
19. Bacci G, Ferrari S, Mercuri M, et al. Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthop Scand 1998;69:230-236.
20. Picci P, Sangiorgi L, Bahamonde L, et al. Risk factors for local recurrences after limb-salvage surgery for high-grade osteosarcoma of the extremities. Ann Oncol 1997;8:899-903.
21. Whelan J, McTiernan A, Cooper N, et al. Incidence and survival of malignant bone sarcomas in England 1979-2007. Int J Cancer 2012;131:E508-E517.
22. Weeden S, Grimer RJ, Cannon SR, Taminiau AH, Uscinska BM; European Osteosarcoma Intergroup. The effect of local recurrence on survival in resected osteosarcoma. Eur J Cancer 2001;37:39-46.
23. Rodriguez-Galindo C, Shah N, McCarville MB, et al. Outcome after local recurrence of osteosarcoma: the St. Jude Children's Research Hospital experience (1970-2000). Cancer 2004;100:1928-1935.
24. Grimer RJ, Sommerville S, Warnock D, et al. Management and outcome after local recurrence of osteosarcoma. Eur J Cancer 2005;41:578-583.
25. Ongolo-Zogo P, Thiesse P, Sau J, et al. Assessment of osteosarcoma response to neoadjuvant chemotherapy: comparative usefulness of dynamic gadoliniumenhanced spin-echo magnetic resonance imaging and technetium-99m skeletal angioscintigraphy. Eur Radiol 1999;9:907-914.
26. Reddick WE, Wang S, Xiong X, et al. Dynamic magnetic resonance imaging of regional contrast access as an additional prognostic factor in pediatric osteosarcoma. Cancer 2001;91:2230-2237.
27. Baunin C, Schmidt G, Baumstarck K, et al. Value of diffusion-weighted images in differentiating mid-course responders to chemotherapy for osteosarcoma compared to the histological response: preliminary results. Skeletal Radiol 2012;41:1141-1149.
28. Uhl M, Saueressig U, Koehler G, et al. Evaluation of tumour necrosis during chemotherapy with diffusion-weighted MR imaging: preliminary results in osteosarcomas. Pediatr Radiol 2006;36:1306-1311.
29. Pakos EE, Nearchou AD, Grimer RJ, et al. Prognostic factors and outcomes for osteosarcoma: an international collaboration. Eur J Cancer 2009;45:2367-2375.
30. Bramer JA, Abudu AA, Grimer RJ, Carter SR, Tillman RM. Do pathological fractures influence survival and local recurrence rate in bony sarcomas? Eur J Cancer 2007;43:1944-1951.
31. Salunke SS, Chen Y, Tan JH et al. Does a pathological fracture affect the prognosis in patients with osteosarcoma of the extremities? A systematic review and metaanalysis. Bone Joint J 2014;96-B:1396-1403.